{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:57:30Z","timestamp":1778651850345,"version":"3.51.4"},"reference-count":36,"publisher":"JLE","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1684\/ejd.2018.3448","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:21:11Z","timestamp":1696864871000},"page":"775-783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study"],"prefix":"10.1684","volume":"28","author":[{"given":"Johan","family":"Hansson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Bartley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Kunstfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Fife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Scott","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeun Mi","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Dimier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fittipaldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Basset-S\u00e9guin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2019,5,6]]},"reference":[{"key":"3448_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s13671-014-0069-y","volume":"3","author":"SV Mohan","year":"2014","unstructured":"Mohan SV, Chang AL. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr Dermatol Rep 2014; 3: 40\u20135.","journal-title":"Curr Dermatol Rep"},{"key":"3448_CR2","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1056\/NEJMra044151","volume":"353","author":"AI Rubin","year":"2005","unstructured":"Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005; 353: 2262\u20139.","journal-title":"N Engl J Med"},{"key":"3448_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s13555-015-0081-6","volume":"5","author":"AW Steenrod","year":"2015","unstructured":"Steenrod AW, Smyth EN, Bush EN, et al. A qualitative comparison of symptoms and impact of varying stages of basal cell carcinoma. Dermatol Ther (Heidelb) 2015; 5: 183\u201399.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3448_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.6004\/jnccn.2016.0065","volume":"14","author":"CK Bichakjian","year":"2016","unstructured":"Bichakjian CK, Olencki T, Aasi SZ, et al. Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 574\u201397.","journal-title":"J Natl Compr Canc Netw"},{"key":"3448_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CCO.0b013e32835ff438","volume":"25","author":"A Sekulic","year":"2013","unstructured":"Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol 2013; 25: 218\u201323.","journal-title":"Curr Opin Oncol"},{"key":"3448_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2016.06.020","volume":"75","author":"G Goldenberg","year":"2016","unstructured":"Goldenberg G, Karagiannis T, Palmer JB, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol 2016; 75: 957\u201366.e2.","journal-title":"J Am Acad Dermatol"},{"key":"3448_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10227-005-0027-1","volume":"9","author":"PT Ting","year":"2005","unstructured":"Ting PT, Kasper R, Arlette JP. Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg 2005; 9: 10\u20135.","journal-title":"J Cutan Med Surg"},{"key":"3448_CR8","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/bjc.2014.270","volume":"111","author":"JT Lear","year":"2014","unstructured":"Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014; 111: 1476\u201381.","journal-title":"Br J Cancer"},{"key":"3448_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/fon.14.281","volume":"11","author":"K Peris","year":"2015","unstructured":"Peris K, Licitra L, Ascierto PA, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol 2015; 11: 703\u201312.","journal-title":"Future Oncol"},{"key":"3448_CR10","volume-title":"Erivedge (vismodegib) [summary of product characteristics]","author":"Roche Products Ltd.","year":"2016","unstructured":"Roche Products Ltd. Erivedge (vismodegib) [summary of product characteristics]. Welwyn Garden City, UK: Roche Products Ltd, 2016. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002602\/WC500146817.pdf (accessed February 27, 2018)."},{"key":"3448_CR11","volume-title":"Erivedge (vismodegib) [prescribing information]","author":"Genentech USA Inc.","year":"2017","unstructured":"Genentech USA Inc. Erivedge (vismodegib) [prescribing information]. South San Francisco, CA: Genentech USA Inc., 2017. Available at: https:\/\/www.gene.com\/download\/pdf\/erivedge_prescribing.pdf (accessed February 27, 2018)."},{"key":"3448_CR12","volume-title":"Odomzo (sonidegib) [prescribing information]","author":"Novartis Pharmaceuticals Corporation","year":"2015","unstructured":"Novartis Pharmaceuticals Corporation. Odomzo (sonidegib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2015. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/205266s000lbl.pdf (accessed February 27, 2018)."},{"key":"3448_CR13","volume-title":"Odomzo (sonidegib) [summary of product characteristics]","author":"Sun Pharmaceutical Industries Europe BV","year":"2017","unstructured":"Sun Pharmaceutical Industries Europe BV. Odomzo (sonidegib) [summary of product characteristics]. Hoffddorp, Netherlands: Sun Pharmaceutical Industries Europe BV, 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/uman\/002839\/WC500192970.pdf (accessed February 27, 2018)."},{"key":"3448_CR14","first-page":"197","volume":"5","author":"MA Macha","year":"2013","unstructured":"Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res 2013; 5: 197\u2013203.","journal-title":"Cancer Manag Res"},{"key":"3448_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nrc2503","volume":"8","author":"EH Epstein","year":"2008","unstructured":"Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743\u201354.","journal-title":"Nat Rev Cancer"},{"key":"3448_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF00434740","volume":"5","author":"S Blackford","year":"1996","unstructured":"Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res 1996; 5: 191\u20134.","journal-title":"Qual Life Res"},{"key":"3448_CR17","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/ajd.12323","volume":"57","author":"EH Lee","year":"2016","unstructured":"Lee EH, Klassen AF, Lawson JL, Cano SJ, Scott AM, Pusic AL. Patient experiences and outcomes following facial skin cancer surgery: a qualitative study. Australas J Dermatol 2016; 57: e100\u20134.","journal-title":"Australas J Dermatol"},{"key":"3448_CR18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/ajd.12205","volume":"56","author":"C Gaulin","year":"2015","unstructured":"Gaulin C, Sebaratnam DF, Fernandez-Penas P. Quality of life in non-melanoma skin cancer. Australas J Dermatol 2015; 56: 70\u20136.","journal-title":"Australas J Dermatol"},{"key":"3448_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jamadermatol.2013.5870","volume":"150","author":"SD Mathias","year":"2014","unstructured":"Mathias SD, Chren M-M, Colwell HH, et al. Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. JAMA Dermatol 2014; 150: 169\u201376.","journal-title":"JAMA Dermatol"},{"key":"3448_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/bjd.12269","volume":"168","author":"AS Bates","year":"2013","unstructured":"Bates AS, Davis CR, Takwale A, Knepil GJ. Patient-reported outcome measures in nonmelanoma skin cancer of the face: a systematic review. Br J Dermatol 2013; 168: 1187\u201394.","journal-title":"Br J Dermatol"},{"key":"3448_CR21","first-page":"511","volume":"50","author":"M Ghajarzadeh","year":"2012","unstructured":"Ghajarzadeh M, Ghiasi M, Kheirkhah S. Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata. Acta Med Iran 2012; 50: 511\u20135.","journal-title":"Acta Med Iran"},{"key":"3448_CR22","first-page":"15","volume":"256","author":"MJ Tidman","year":"2012","unstructured":"Tidman MJ. Prompt treatment of acne improves quality of life. Practitioner 2012; 256: 15\u20137, 2.","journal-title":"Practitioner"},{"key":"3448_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/MLG.0b013e31802e2d88","volume":"117","author":"JS Rhee","year":"2007","unstructured":"Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399\u2013405.","journal-title":"Laryngoscope"},{"key":"3448_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1470-2045(15)70198-1","volume":"16","author":"N Basset-Seguin","year":"2015","unstructured":"Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015; 16: 729\u201336.","journal-title":"Lancet Oncol"},{"key":"3448_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 86: 334\u201348.","journal-title":"Eur J Cancer"},{"key":"3448_CR26","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory. Cancer 2000; 89: 1634\u201346.","journal-title":"Cancer"},{"key":"3448_CR27","first-page":"525","volume":"30","author":"JS Rhee","year":"2004","unstructured":"Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004; 30: 525\u20139.","journal-title":"Dermatol Surg"},{"key":"3448_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02737863","volume":"5","author":"MM Chren","year":"2001","unstructured":"Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105\u201310.","journal-title":"J Cutan Med Surg"},{"key":"3448_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.jid.5700740","volume":"127","author":"M-M Chren","year":"2007","unstructured":"Chren M-M, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007; 127: 1351\u20137.","journal-title":"J Invest Dermatol"},{"key":"3448_CR30","volume-title":"MD Anderson Symptom Inventory User Guide","author":"CS Cleeland","year":"2016","unstructured":"Cleeland CS. MD Anderson Symptom Inventory User Guide. University of Texas MD Anderson Cancer Center, 2016. Available at: https:\/\/www.mdanderson.org\/documents\/Departments-and-Divisions\/Symptom-Research\/MDASI_userguide.pdf (accessed February 27, 2018)."},{"key":"3448_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jama.2013.6855","volume":"310","author":"E Basch","year":"2013","unstructured":"Basch E, Torda P, Adams K. Standards for patient-reported outcome-based performance measures. JAMA 2013; 310: 139\u201340.","journal-title":"JAMA"},{"key":"3448_CR32","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.jaad.2012.09.017","volume":"69","author":"EH Lee","year":"2013","unstructured":"Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of non-melanoma skin cancer in the dermatologic population. J Am Acad Dermatol 2013; 69: e59\u201367.","journal-title":"J Am Acad Dermatol"},{"key":"3448_CR33","first-page":"248","volume-title":"The assessment of reliability. Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH. The assessment of reliability. Psychometric theory, 3rd ed. New York: McGraw-Hill, 1994, p. 248\u201392.","edition":"3rd ed."},{"key":"3448_CR34","first-page":"5s","volume":"32","author":"A Sekulic","year":"2014","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update (30-month) of the pivotal ERIVANCE BCC study. J Clin Oncol 2014; 32: 5s.","journal-title":"J Clin Oncol"},{"key":"3448_CR35","first-page":"6","volume":"8","author":"MR Migden","year":"2017","unstructured":"Migden MR. Quality of life for patients with advanced basal cell carcinoma treated with hedgehog signaling pathway inhibitors. J Clin Exp Dermatol Res 2017; 8:6.","journal-title":"J Clin Exp Dermatol Res"},{"key":"3448_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716\u201328.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2018.3448\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:23:29Z","timestamp":1741191809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3448"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2018.3448","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"13 Juli 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 Mai 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}